Journal: Advanced Science

Article Title: Nanozyme‐Engineered Probiotic Microneedle Patch for Chronic Diabetic Wound Therapy

doi: 10.1002/advs.202512127

Figure Lengend Snippet: Antioxidant and anti‐inflammatory effects of Pt‐M NZ in vitro. a) Schematic illustration of Pt‐M NZ mitigating cellular oxidative stress through ROS scavenging. b) Representative ROS staining images and c) quantitative analysis of mean fluorescence intensity in HaCaT and NIH‐3T3 cells after incubation with DCFH‐DA probe. d) Flow cytometry results and e) quantitative analysis of median fluorescence intensity in HaCaT cells stained with DCFH‐DA under different treatments. f) SOD and g) CAT enzyme activities in HaCaT cells and NIH‐3T3 cells after different treatments. h) Flow cytometry analysis of macrophage polarization and i) quantitative M2Φ/M1Φ ratios under different treatments. j) Confocal laser scanning microscopy images and l) relative fluorescence intensity quantification of TNF‐α in RAW 264.7 cells. k) Confocal laser scanning microscopy images and m) relative fluorescence intensity quantification of IL‐6 in RAW 264.7 cells. Relative expression of n) TNF‐α and o) IL‐6 in RAW 264.7 cells determined by RT‐qPCR after different treatments. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Article Snippet: Antibodies against TNF‐α, IL‐6, and HIF‐1α were purchased from MCE (USA).

Techniques: In Vitro, Staining, Fluorescence, Incubation, Flow Cytometry, Confocal Laser Scanning Microscopy, Expressing, Quantitative RT-PCR

Journal: Advanced Science

Article Title: Nanozyme‐Engineered Probiotic Microneedle Patch for Chronic Diabetic Wound Therapy

doi: 10.1002/advs.202512127

Figure Lengend Snippet: Histopathological analysis of diabetic infected wounds on day 15 post‐treatment. Representative bright‐field microscopy images of a) H&E staining, b) Masson staining, and c) immunohistochemistry staining of IL‐6 after different treatments (Red arrows indicate IL‐6‐positive cells). d) Representative immunofluorescence microscopy images of CD31 after different treatments (Yellow arrows indicate sites of neovascularization). e) Quantitative analysis of collagen volume fraction (CVF) for different treatments. f) Quantitative analysis of positive areas for IL‐6 immunohistochemical staining. g) Quantitative analysis of the relative coverage area of CD31 for different treatments. Each point represents mean ± SD (n = 5). * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. The ns indicates no significance.

Article Snippet: Antibodies against TNF‐α, IL‐6, and HIF‐1α were purchased from MCE (USA).

Techniques: Infection, Microscopy, Staining, Immunohistochemistry, Immunofluorescence, Immunohistochemical staining

Journal: Journal of Cellular and Molecular Medicine

Article Title: Complement 5a‐mediated trophoblasts dysfunction is involved in the development of pre‐eclampsia

doi: 10.1111/jcmm.13466

Figure Lengend Snippet: Expression of angiogenesis‐related factors in human placenta. ( A ) Relative mRNA levels of anti‐angiogenic factors ( IL ‐1β, TNF ‐α, IL ‐6, MCP ‐1 and sF lt1) and pro‐angiogenic ( PIGF , IL ‐10) in normal and pre‐eclamptic placentas. Data are represented as mean ± S.E.M. N = 4–6 in each group. * P < 0.05, ** P < 0.01, *** P < 0.001. ( B ) Immunofluorescence analysis of representative angiogenesis‐related factors (red) and Cy7 (green) in normal and PE placentas. Nuclei were counterstained with DAPI (blue). Scale bar: 60 μm.

Article Snippet: The human placenta slices were blocked in 10% normal goat serum for 30 min., then incubated with primary antibodies against CD31 (Santa Cruz), CD11b (BD Biosciences, San Jose, CA, USA), C5a (Comp Tech, A221), C5aR (Biolegend), cytokeratin 7 (Cy7, Santa Cruz), PIGF (Proteintech group, Wuhan, Hubei, China), sFlt1 (Life Technologies, Waltham, MA, USA), IL‐1β (Boster), IL‐6 (Boster) and MCP‐1 (Boster, Wuhan, Hubei, China) at 4°C overnight.

Techniques: Expressing, Immunofluorescence

Journal: Journal of Cellular and Molecular Medicine

Article Title: Complement 5a‐mediated trophoblasts dysfunction is involved in the development of pre‐eclampsia

doi: 10.1111/jcmm.13466

Figure Lengend Snippet: Trophoblasts stimulated with C5a display an anti‐angiogenic phenotype. ( A ) HTR ‐8/ SV neo cells treated with C5a showed a polarization towards an anti‐angiogenic phenotype with significantly increased mRNA levels of IL ‐1β, TNF ‐α, IL ‐6, MCP ‐1, sF lt1 and decreased mRNA level of PIGF and IL ‐10. The respective mRNA was normalized to β‐actin housekeeping gene. Data are represented as mean ± S.E.M . N = 3 in each group * P < 0.05, ** P < 0.01. ( B ) Immunofluorescence staining for sF lt1 and PIGF expression in HTR ‐8/ SV neo cells in the presence of C5a or PBS ( CON ). Scale bar: 60 μm.

Article Snippet: The human placenta slices were blocked in 10% normal goat serum for 30 min., then incubated with primary antibodies against CD31 (Santa Cruz), CD11b (BD Biosciences, San Jose, CA, USA), C5a (Comp Tech, A221), C5aR (Biolegend), cytokeratin 7 (Cy7, Santa Cruz), PIGF (Proteintech group, Wuhan, Hubei, China), sFlt1 (Life Technologies, Waltham, MA, USA), IL‐1β (Boster), IL‐6 (Boster) and MCP‐1 (Boster, Wuhan, Hubei, China) at 4°C overnight.

Techniques: Immunofluorescence, Staining, Expressing

Journal: bioRxiv

Article Title: Hypercholesterolemia aggravates in-stent restenosis in rabbits: a mitigating effect of stent surface modification with CD47-derived peptide

doi: 10.1101/2023.02.27.530304

Figure Lengend Snippet: (A-P) Representative microscopic images (100x magnification) of iliac arteries stented with BMS (A, B, E, F, I, J, M, N) and pepCD47-functionalized stents (C, G, K, O) and immunostained for TNFα (A-C), IL1β (E-G), IL6 (I-K) and CD68-positive macrophages (M-O). Quantification of TNFα (D), IL1β (H), and IL6 (L) expression was based on a semi-quantitative (0-4) scale. Macrophage infiltration around the struts (P) was calculated as a percentage of a strut circumference occupied with the CD68-positive cells (n=4 for each marker/treatment group combination).

Article Snippet: Primary antibodies to rabbit CD68, TNFα, IL1β, and IL6 were from ProSci (Poway, CA, USA), MyBioSource (San Diego, CAS, USA), Bioss (Woburn, MA, USA), and Abbexa (Cambridge, UK), respectively.

Techniques: Expressing, Marker